Experts Answer Questions on Current and Emerging Options for Hemophilia A Management

In this podcast episode, 3 experts answers questions on the management of hemophilia A from a live webinar. Topics include: Which patients should have pharmacokinetic-guided therapy?Toxicities with PEGylated extended half-life productsFactor VIII and bone healthFactor VIII peaks, thrombotic risk, and cardiovascular diseaseChoosing between extended half-life products and emicizumab for active patientsRole of fitusiran in the treatment paradigm if approvedPresenters:Miguel A. Escobar, MDProfessor of Medicine and PediatricsDepartment of HematologyUniversity of Texas Health Science CenterMcGovern Medical SchoolDirectorGulf States Hemophilia and Thrombophilia CenterHouston, TexasMark Reding, MDProfessor of MedicineDivision of Hematology, Oncology, and TransplantationDirectorCenter for Bleeding and Clotting DisordersUniversity of MinnesotaMinneapolis, MinnesotaGuy A. Young, MDProfessor of PediatricsDirector, Hemostasis and Thrombosis CenterChildren’s Hospital Los AngelesUniversity of Southern California Keck School of MedicineLos Angeles, CaliforniaLink to full program, including downloadable slidesets, expert commentary, and on-demand webcast:https://bit.ly/3zZwP6G

There are no comments yet.

Please log in to write the first comment.